2L9 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Blueprint Medicines Corp

Watchlist Manager

Watchlist

Price: 110.05 EUR Market Closed

Market Cap: €6.9B

B	Blueprint Medicines Corp F:2L9	US
W	Whoosh Holding PAO MOEX:WUSH	RU
A	AAPICO Hitech PCL SET:AH	TH
F	Food Moments PCL SET:FM	TH
J	Jasa Marga (Persero) Tbk PT F:0JM	ID
C	Compagnie de Saint Gobain SA DUS:GOB	FR
	NewPrinces SpA F:6NF	IT
H	HSBC Holdings PLC XMUN:HBC2	UK
	Strategic Partners A/S CSE:STRAP	DK
	Sulzer AG SIX:SUN	CH
S	SIS Distribution Thailand PCL SET:SIS	TH
G	GEVORKYAN as PSE:GEV	SK

Profitability Summary

Blueprint Medicines Corp's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

96%

Strong 3Y Average Gross Margin

97%

Gross Margin is Increasing

94% > 96%

Negative Operating Margin

-31%

Negative 3Y Average Operating Margin

-98%

Operating Margin is Increasing

-245% > -31%

Negative Net Margin

-28%

Negative 3Y Average Net Margin

-72%

Net Margin is Increasing

-256% > -28%

Negative Free Cash Flow Margin

-27%

Negative 3Y Average Free Cash Flow Margin

-92%

Free Cash Flow Margin is Increasing

-228% > -27%

Negative ROE

-48%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-81%

ROIC is Increasing

-152% > -35%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.